Helicobacter pylori binding to new glycans based on N-acetyllactosamine.
Previously we reported binding of Helicobacter pylori to various nonacid and sialylated neolacto carbohydrate structures using a wide range of natural and chemically modified sequences. A novel nonsialylated neolacto-based binding epitope, GlcNAc beta 3Gal beta 4GlcNAc, and analogous structures carrying terminal GalNAc beta 3, GalNAc alpha 3, or Gal alpha 3 showed the binding activity (Miller-Podraza H, Lanne B, Angström J, Teneberg S, Abul-Milh M, Jovall P-A, Karlsson H, Karlsson K-A. 2005. Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains. J Biol Chem. 280:19695-19703). The present work reports two other H. pylori-binding nonsialylated neolacto-based structures, GlcA beta 3Gal beta 4GlcNAc beta 3-R and Glc beta 3Gal beta 4GlcNAc beta 3-R, and two amide derivatives (N-methyl and N-ethyl) of GlcA beta 3Gal beta 4GlcNAc beta 3-R which were bound by H. pylori. The latter structures turned out to be more effective as H. pylori binders than the parent saccharide. New reducing-end variants of the neolacto epitope including species containing N-acetyllactosamine linked beta 6 to GlcNAc or Gal with similarity to branched polylactosamines and mucins were prepared and tested. The results extend our previous findings on binding specificities of H. pylori and show that this pathogen is able to interact with an array of N-acetyllactosamine/neolacto structures, which may be of importance for the in vivo interaction of the bacterium with human cells. The information gained in this work may also be of value for rational design of anti-H. pylori drugs.
Miller-Podraza
Halina
H
Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Göteborg University, Box 440, SE 405 30 Göteborg, Sweden. Halina.Miller-Podraza@medkem.gu.se
Weikkolainen
Krista
K
Larsson
Thomas
T
Linde
Petra
P
Helin
Jari
J
Natunen
Jari
J
Karlsson
Karl-Anders
KA
D000117:Acetylglucosamine / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology; D001422:Bacterial Adhesion / Q000187:drug effects / Q000502:physiology*; D000939:Epitopes / Q000737:chemistry* / Q000494:pharmacology; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans
D000939:Epitopes; D000117:Acetylglucosamine